GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shine-On BioMedical Co Ltd (ROCO:6926) » Definitions » EV-to-EBITDA

Shine-On BioMedical Co (ROCO:6926) EV-to-EBITDA : -19.21 (As of Jul. 17, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Shine-On BioMedical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shine-On BioMedical Co's enterprise value is NT$2,235.78 Mil. Shine-On BioMedical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-116.37 Mil. Therefore, Shine-On BioMedical Co's EV-to-EBITDA for today is -19.21.

The historical rank and industry rank for Shine-On BioMedical Co's EV-to-EBITDA or its related term are showing as below:

ROCO:6926' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.71   Med: -64.7   Max: -19.21
Current: -19.21

During the past 6 years, the highest EV-to-EBITDA of Shine-On BioMedical Co was -19.21. The lowest was -67.71. And the median was -64.70.

ROCO:6926's EV-to-EBITDA is ranked worse than
100% of 464 companies
in the Biotechnology industry
Industry Median: 10.165 vs ROCO:6926: -19.21

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-17), Shine-On BioMedical Co's stock price is NT$65.80. Shine-On BioMedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-2.390. Therefore, Shine-On BioMedical Co's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Shine-On BioMedical Co EV-to-EBITDA Historical Data

The historical data trend for Shine-On BioMedical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shine-On BioMedical Co EV-to-EBITDA Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial - - -96.84 -61.98 -20.24

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.84 - -61.98 - -20.24

Competitive Comparison of Shine-On BioMedical Co's EV-to-EBITDA

For the Biotechnology subindustry, Shine-On BioMedical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shine-On BioMedical Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shine-On BioMedical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shine-On BioMedical Co's EV-to-EBITDA falls into.


;
;

Shine-On BioMedical Co EV-to-EBITDA Calculation

Shine-On BioMedical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2235.782/-116.374
=-19.21

Shine-On BioMedical Co's current Enterprise Value is NT$2,235.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shine-On BioMedical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-116.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shine-On BioMedical Co  (ROCO:6926) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Shine-On BioMedical Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=65.80/-2.390
=At Loss

Shine-On BioMedical Co's share price for today is NT$65.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shine-On BioMedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-2.390.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Shine-On BioMedical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shine-On BioMedical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shine-On BioMedical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 633, Section 2, Taiwan Avenue, Unit 6, 5th Floor, Xitun District, Taichung, TWN
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with the most effective cancer treatment options.

Shine-On BioMedical Co Headlines

No Headlines